Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Newer NNRTI Agents in Clinical Practice

27:40
 
Share
 

Manage episode 371092380 series 2065653
Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?

Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.


Take our post-test to claim CME credits.

To read a companion newsletter click here.


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

220 episodes

Artwork

Newer NNRTI Agents in Clinical Practice

DKBmed Radio

14 subscribers

published

iconShare
 
Manage episode 371092380 series 2065653
Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?

Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.


Take our post-test to claim CME credits.

To read a companion newsletter click here.


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

220 episodes

Tüm bölümler

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play